There is clinically relevant molecular heterogeneity in prostate cancer (PCa), but this
biological diversity has had only a minimal impact on clinical practice. Treatment outcomes …

The possibility that a receptor for androgen is expressed in Breast Cancer (BC) is fascinating
given that the tumor is predominantly estrogen-dependent. The androgen receptor (AR) is …

PURPOSE Circulating tumor DNA (ctDNA) sequencing provides a minimally invasive
method for tumor molecular stratification. Commercial ctDNA sequencing is increasingly …

PURPOSE Tumor tissue from metastatic castration-resistant prostate cancer (mCRPC)
harbors frequent copy number variations (CNVs) in the PTEN-PI3K-AKT pathway. However …

Background Because cell‐free DNA (cfDNA) analysis facilitates the noninvasive genomic
profiling of metastatic castration‐resistant prostate cancer (mCRPC), the authors evaluated …

Purpose: Therapies targeting the androgen receptor (AR) have improved the outcome for
patients with castration-sensitive prostate cancer (CSPC). Expression of the constitutively …

Recent advances in DNA profiling techniques have enabled sensitive detection of tumor-
associated genomic aberrations in peripheral blood. This type of minimally-invasive …

ABSTRACT Background Plasma tumour DNA (ptDNA) levels on treatment are associated
with response in a variety of cancers. However, the role of ptDNA in prostate cancer …

Importance Abiraterone acetate is combined with prednisone, 5 mg, twice daily for
metastatic castration-resistant prostate cancer (mCRPC) and with prednisone, 5 mg, once …

Background Genomic alterations to the androgen receptor (AR) are common in metastatic
castration‐resistant prostate cancer (mCRPC). AR copy number amplifications, ligand …